Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.
Respiratory syncytial virus (RSV) is the most important virus mediating lower respiratory tract illness in infants and young children. RSV infection is associated with pulmonary inflammation and increased levels of substance P (SP), making the airways and leukocytes that express SP receptors susceptible to the proinflammatory effects of this peptide. This study examines combining neutralizing anti-F glycoprotein and anti-SP antibody treatment of RSV-infected BALB/c mice to inhibit RSV replication and inflammation associated with infection. BALB/c mice were prophylactically treated with antibody prior to RSV infection or were therapeutically treated at day 2 or 6 post-RSV infection. Prophylactic or therapeutic treatment with anti-SP antibodies promptly reduced pulmonary inflammatory cell infiltration and decreased the number of cells expressing proinflammatory cytokines, while anti-F antibody treatment reduced virus titers. The results suggest that combined anti-viral and anti-SP antibody treatment may be effective in treating RSV disease.
Haynes
Lia M
LM
Respiratory and Enteric Virus Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Tonkin
Joelyn
J
Anderson
Larry J
LJ
Tripp
Ralph A
RA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D005260:Female; D007249:Inflammation / Q000517:prevention & control / Q000628:therapy*; D008168:Lung / Q000276:immunology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control / Q000628:therapy*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D013373:Substance P / Q000276:immunology*; D016896:Treatment Outcome; D014764:Viral Proteins / Q000276:immunology*; D014779:Virus Replication
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D016207:Cytokines; D014764:Viral Proteins; D013373:Substance P